

Epimmune Incorporated

[View the current Epimmune Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/3875-Epimmune+Incorporated.html)

(<http://www.bioportfolio.com/bi corporate/3875-Epimmune+Incorporated.html>)

Contact Details:

5820 Nancy Ridge Drive

San Diego

CA

92121

United States of America

Tel: 858 860 2500

Fax: 858 860 2600

Email:

Epimmune's core business is the development of vaccines to treat and prevent infectious diseases and cancer. Epimmune's business also includes a therapeutic anti-inflammatory program based on cell adhesion inhibitors and its Glytec business unit, encompassing proprietary manufacturing technology for the enzymatic synthesis of bioactive complex carbohydrates.

Recent Publications by Epimmune Incorporated:



- [Measurement of MHC/peptide interactions by gel filtration.](#)

*This unit describes a technique for the direct and quantitative...*6th June, 2008

Epimmune Incorporated, San Diego, California, USA.- Curr Protoc Immunol. 2001 May;Chapter 18:Unit 18.3. ([DOI Direct Link](#))

- [Formulation and Characterization of a Ten-peptide Single-vial Vaccine, EP-2101, Designed to Induce Cytotoxic T-lymphocyte Responses for Cancer Immunotherapy.](#)

*Effective vaccines that mediate clinical responses in cancer patients may...*3rd April, 2008

Pharmexa-Epimmune Inc., 5820 Nancy Ridge Drive, Suite 100, San Diego, CA- Hum Vaccin. 2007 Nov 11;4(3).

- [Rationally engineered therapeutic proteins with reduced immunogenicity.](#)

*Chronic administration of protein therapeutics may elicit unacceptable...*29th April, 2005

Epimmune, San Diego, CA 92121, USA.- J Immunol. 2005 Mar 15;174(6):3187-96.

- [Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.](#)

*Recognition by CD8(+) T lymphocytes (CTL) of epitopes that are derived...*4th November, 2004

Epimmune, San Diego, CA 92121, USA.- J Immunol. 2004 Aug 1;173(3):1941-50.

- [Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope \(PADRE\).](#)

Experimental carbohydrate-conjugate vaccines composed of the 13 amino acid...8th September, 2004
 Epimmune Inc., 5820 Nancy Ridge Drive, Suite 100, San Diego, CA 92121,- Vaccine. 2004 Jun
 23;22(19):2362-7. ([DOI Direct Link](#))

- [Design of multi-epitope, analogue-based cancer vaccines.](#)
The current objective of our cancer programme is to develop an effective...22nd July, 2004
 Epimmune, Inc., 5820 Nancy Ridge Drive, San Diego, CA 92121, USA.- Expert Opin Biol Ther. 2003
 Sep;3(6):985-93. ([DOI Direct Link](#))
- [Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.](#)
*Transgenic mice expressing chimeric human leukocyte antigen (HLA)-B*0702...27th September, 2003*
 Epimmune Inc., San- Hum Immunol. 2003 Feb;64(2):211-23.
- [Rationally engineered proteins or antibodies with absent or reduced immunogenicity.](#)
One challenge associated with the clinical use of protein therapeutics...27th June, 2003
 Epimmune Incorporated, 5820 Nancy Ridge Drive, San Diego, CA-92121, USA.- Curr Med Chem.
 2002 Dec;9(24):2191-9.
- [Optimizing vaccine design for cellular processing, MHC binding and TCR recognition.](#)
In this review we describe the methods and processes that our group have...5th April, 2003
 Epimmune Inc., San Diego, CA 92121, USA.- Tissue Antigens. 2002 Jun;59(6):443-51.
- [Epitope identification and vaccine design for cancer immunotherapy.](#)
The development of processes for engineering multi-epitope vaccines based...18th December, 2002
 Epimmune- Curr Opin Investig Drugs. 2002 Jan;3(1):132-9.
- [The HLA molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 share an extensive overlap in peptide binding specificity.](#)
Assays to measure the binding capacity of peptides for...11th December, 2002
 Epimmune, Inc., San Diego, CA 92121, USA.- J Immunol. 2002 Nov 1;169(9):5098-108.
- [Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses.](#)
Cellular immune responses, specifically those mediated by CD8+ cytotoxic...26th November, 2002
 Epimmune- Curr Opin Investig Drugs. 2002 Mar;3(3):374-8.

Press Releases on Epimmune Incorporated:

H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics	20th November, 2009	Quest Diagnostics Incorporated	<i>-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during</i>
New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)	20th November, 2009	Quest Diagnostics Incorporated	<i>MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,</i>

Spherix Announces the Closing of \$6.3 Million Registered Direct Offering	19th November, 2009	Spherix Incorporated	<p>BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting</p>
Spherix Announces Results of Annual Shareholders Meeting	19th November, 2009	Spherix Incorporated	<p>-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods International In addition, Grant Thornton LLP was ratified as the Company's independent accountants</p>
Give Your Pooch the Gift of Wisdom This Holiday	19th November, 2009	Mars Veterinary	<p>ROCKVILLE, Md., Nov. 19 /PRNewswire/ -- There is no greater love than the adoration you receive from man's best friend. This holiday season, return the love by gifting your four legged friend</p>

Epimmune Incorporated Clinical Trials:



- [A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine \(EP HIV-1090\) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy \(ART\)](#)

Epimmune Incorporated Patents:



- 7026443- [Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions](#)
- 6322789- [HLA-restricted hepatitis B virus CTL epitopes](#)
- 6413517- [Identification of broadly reactive DR restricted epitopes](#)
- 6413935- [Induction of immune response against desired determinants](#)

- 6419931- [Compositions and methods for eliciting CTL immunity](#)
- 6464980- [MAGE-1 c-terminal immunogenic peptides](#)
- 6534482- [Expression vectors for stimulating an immune response and methods of using the same](#)
- 6602510- [HLA class I A2 tumor associated antigen peptides and vaccine compositions](#)
- 6689363- [Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions](#)
- 6037135- [Methods for making HLA binding peptides and their uses](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

